Lantern Wealth Advisors’s AbCellera Biologics ABCL Stock Holding History

Lantern Wealth Advisors’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$34.9K	Buy	+10,000	New	+$36K	0.02%	173
2025 Q4	–	Sell	-15,000	Closed	-$75.5K	–	164
2025 Q3	$75.5K	Hold	15,000	–	–	0.04%	153
2025 Q2	$51.5K	Buy	+15,000	New	+$37.3K	0.03%	147
2024 Q4	$52.7K	Sell	18,000 -5,300	-23%	-$14.8K	0.03%	134
2024 Q3	$60.6K	Hold	23,300	–	–	0.04%	127
2024 Q2	$69K	Buy	23,300 +750	+3%	+$2.84K	0.05%	128
2024 Q1	$102K	Hold	22,550	–	–	0.07%	126
2023 Q4	$129K	Buy	+22,550	New	+$105K	0.1%	113

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Lantern Wealth Advisors's ABCL Position: Q1 2026 in Review

Lantern Wealth Advisors opened a new position in AbCellera Biologics (ABCL) in Q1 2026: 10,000 shares worth $34.9K. The stake represents 0.02% of the portfolio and ranks #173 among its holdings. This is a return to the name: Lantern Wealth Advisors previously reported a position in ABCL as recently as Q3 2025.

Lantern Wealth Advisors first reported a position in ABCL in Q4 2023 and has held it in 8 quarters since. The position peaked at $129K in Q4 2023. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Lantern Wealth Advisors held 10,000 shares of AbCellera Biologics worth $34.9K as of Q1 2026.
AbCellera Biologics was a new Lantern Wealth Advisors position in Q1 2026.
AbCellera Biologics made up 0.02% of Lantern Wealth Advisors's portfolio in Q1 2026, its #173 holding.
Lantern Wealth Advisors first reported a position in AbCellera Biologics in Q4 2023 and has held it in 8 quarters since.
Lantern Wealth Advisors's AbCellera Biologics position peaked at $129K in Q4 2023.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Lantern Wealth Advisors's 13F filing for Q1 2026, filed 13 May 2026.